Article

Retina Roundtable Session 3

Subscribe

In this third session, the physicians discuss how they communicate to their patients the increased risk of stroke that may be associated with dosing of anti-VEGF agents.

Participants include:

Return to Retina Roundtable Podcast Series

Return to Ophthalmology Times Radio

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Tenpoint Therapeutics Ltd. appoints Carol Kearney as Chief Commercial Officer
March 12th 2025

Tenpoint Therapeutics Ltd. appoints Carol Kearney as Chief Commercial Officer

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

FDA accepts new drug application for low-dose atropine from Sydnexis
March 11th 2025

FDA accepts new drug application for low-dose atropine from Sydnexis

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Renal dysfunction may affect intravitreal conbercept effectiveness in diabetic macular edema treatment
March 11th 2025

Renal dysfunction may affect intravitreal conbercept effectiveness in diabetic macular edema treatment

(Image credit: AdobeStock/©KayExam/peopleimages.com)
March 10th 2025

A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey

© 2025 MJH Life Sciences

All rights reserved.